top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium...
3 hours ago
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ), ("Alpha Tau" or the "Company"), the developer of the...
May 13
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 6, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 6
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
- Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S....
Apr 28
bottom of page